Ochsner Neurocognitive Program · For internal medicine & primary care

Physician Referral Guide

Brain health, cognitive impairment and dementia — how to evaluate, manage and refer, including anti-amyloid therapy. Most patients need only 2–3 answers to find the right route.

~30–40 days down from ~117Wait time when the full workup is complete before referral — p-tau217, MRI with SWI, and a MoCA on the chart
~12 vs ~50 monthsModeled specialist wait when a positive blood biomarker is required before referral, versus a cognitive screen alone (national modeling)
Earlier is betterDisease stage at the time of treatment is the dominant variable in anti-amyloid benefit
Start here

The short version

1 ScreenMoCA plus a family member’s account of what has changed (CANTAB coming).
2 LabsEveryone: B1, B12, folate (B9), MMA, homocysteine, CBC, CMP and TSH. RPR in the appropriate population. Add plasma p-tau217 only with objective impairment (MoCA 26 or below, or abnormal exam) — never in asymptomatic patients.
3 ImageMRI brain without contrast. SWI is needed for any anti-amyloid (AAT) pathway.
4 Review medsStop or reduce anticholinergics, benzodiazepines and sedative sleep aids.
5 RouteUse the route finder or If-Then table. Positive p-tau217 with MCI or mild dementia → Referral 46, flagged as a possible AAT candidate.
6 Keep managingSleep, mood, hearing, vascular risk, safety, driving, firearms and caregiver support. Moderate-stage dementia → palliative care partnership.
Interactive

Find the right route

Answer a few questions about your patient. You’ll get the order to place, who to copy, and a referral comment you can paste.

Route finder

2–3 taps
Blood biomarker

How to read plasma p-tau217

p-tau217 answers one question: is Alzheimer amyloid likely present? It does not diagnose dementia, stage disease, or explain every symptom.

Negative
AD unlikely
Stay in primary care; look for other causes (sleep, mood, medications, vascular). If concern persists, Referral 46 general neurology route.
Intermediate (about 1 in 6)
Indeterminate
Consider amyloid PET. Do not simply repeat the blood test. Interpret with eGFR and hemoglobin in mind.
Positive
AD amyloid likely
MCI or mild dementia: Referral 46 to Cognitive Neurology, comment “positive p-tau217, possible anti-amyloid candidate”, CC the Neurocognitive triage pool. Moderate or later stage: AAT is not an option; focus on support (palliative care or 85+ clinic).
Routing

Where to send: If-Then table

Stay in primary careRefer / work upPossible AATCAASupportive & alliedUrgent
Cognitive complaint, normal MoCA, normal function
Stay in primary care. Treat sleep, mood, hearing, medications. Repeat MoCA in 6 to 12 months. No p-tau217.
MCI or mild dementia, cause unclear
Referral 46, general neurology route. Specific questions: the Neurocognitive Program, through the triage pool.
MCI or mild dementia plus intermediate p-tau217
Consider amyloid PET.
MCI or mild dementia plus positive p-tau217
Referral 46 flagged as possible AAT candidate; CC the Neurocognitive triage pool.
Microbleeds, siderosis, lobar hemorrhage (suspected CAA)
CAA Clinic (504-842-6179). Questions: the CAA Clinic’s vascular neurology team.
Vascular cognitive impairment
Referral 46; questions to the CAA Clinic’s vascular neurology team. Tight BP, glucose, lipid control.
Moderate-stage dementia (needs help with basic self-care, FAST 5+)
Palliative care for longitudinal follow-up and hospice planning; neurology helps with behavior issues as they arise.
Age 85+, or later stage focused on support
85+ clinic via Referral 47 (books months out).
Predominant language or swallowing problems
Speech-language therapy. Do not refer for memory alone.
Falls, home safety, driving concerns
Occupational therapy (home safety, driving evaluation).
Insomnia or night waking
Sleep steps (see Ongoing care) and Sleep Medicine.
Caregiver stress, paperwork, finances, placement
Social work from primary care; no neurology referral needed.
Hallucinations, parkinsonism, dream enactment
Referral 46 listing features. Avoid antipsychotics where possible.
Sudden confusion, rapid decline, danger to self or others
Emergency Department (see Ongoing care → Emergencies).
No match — try another word, or ask one of the contacts.

Which order: 46 or 47?

46Neurology, Memory Disorders
Goes to
Neurology triage. General or virtual neurology sees first and escalates; a complete AAT workup routes to the AAT pipeline.
Use for
New cognitive concern needing a neurologic diagnosis; possible AAT candidates; CAA; Lewy body, FTD, atypical features; vascular cognitive impairment.
Scheduling
Neurology referral team calls the patient.
47Adult Neuropsychology
Goes to
Neuropsychology team. Does not reach Cognitive Neurology.
Use for
Formal testing questions (baseline, capacity, unclear diagnosis); patients 85 and older (85+ clinic).
Scheduling
Neuropsychology team.
  • Patient already sees a neurologist for something else? Write “new cognitive concern, memory disorders triage” in the comments so they aren’t booked back into the wrong clinic.
  • Not appropriate for AAT or cognitive neurology? Send to general neurology first rather than directly to neuropsychology — it avoids long waits and referral loops.

What happens after you refer

  1. 1Chart review triageMinimum AAT criteria met → AAT clinic pipeline; otherwise the general / non-AAT neurology pipeline.
  2. 2RN intake callA clinical navigator confirms goals of care and prior workup, explains the process and collects outside records.
  3. 3Vanguard visitPA + nursing complete the preliminary workup and cognitive testing, educate patient and family, and triage.
  4. 4Diagnostic visitMD or MD + PA. If cleared → AAT pathway; if not eligible → non-AAT management.
  5. 5One RN ownerA Brain Health or Infusion Navigator owns AAT, palliative and hospice transitions — one RN at each stage.

VIP or expedite requests: route through the Neurocognitive triage pool so the same pathway is followed.

In primary care

The initial workup

History & screening

  • Who noticed, what changed, when it started, and whether the course is gradual, stepwise or rapid.
  • Daily function: independent; needs help with bills, medications, driving (IADLs); or needs help with bathing, dressing, toileting (basic ADLs — suggests moderate stage).
  • MoCA: record score and years of education. A normal MoCA does not exclude early change in highly educated or high-reserve patients.
  • Red flags: hallucinations, parkinsonism, dream enactment (Lewy body); behavior or personality change (FTD); predominant language problems (PPA); stepwise decline or strokes (vascular).
  • Sleep apnea: screen everyone (snoring, witnessed apneas, daytime sleepiness, sleep aids). Order sleep testing when symptoms or risk factors are present, not reflexively.
  • Mood, hearing, alcohol use, and safety (driving, firearms, living alone).

Imaging

  • MRI brain without contrast is the default. Use contrast only for specific concerns (encephalitis or inflammation, tumor, another lesion).
  • MRI within 12 months with SWI is part of the minimum AAT referral workup. The neurocognitive team adds the AAT safety MRI if needed.
  • Microbleeds, superficial siderosis or lobar hemorrhage suggest cerebral amyloid angiopathy (CAA) and change routing.

Medication review

Often the single most helpful intervention. Treat it as an advisory review prompt, not a hard stop.

  • Highest yield: strong anticholinergics, benzodiazepines and sedative-hypnotics, opioids, topiramate and other centrally acting agents. Consider cumulative anticholinergic burden (ACB or Drug Burden Index).
  • Indirect mechanisms: hypoglycemia, hyponatremia, drug accumulation with renal or hepatic impairment (e.g. valacyclovir confusion with reduced renal function).
  • Never stop abruptly: benzodiazepines, antiseizure drugs, baclofen, opioids, corticosteroids — taper and substitute.
  • Donepezil and memantine initiation in primary care: program guidance pending.

Laboratory evaluation

TestWhenPractical notes
Vitamin B1 (thiamine)EveryonePart of the standard cognitive lab panel.
Vitamin B12EveryoneNeurocognitive practice supplements below 400 pg/mL in patients with cognitive symptoms. Read with MMA: low-normal B12 with elevated MMA supports functional deficiency.
Folate (vitamin B9)EveryoneEspecially relevant with malnutrition, alcohol use, malabsorption or macrocytosis.
Methylmalonic acid (MMA)EveryoneOrder with B12 — elevated MMA with low-normal B12 supports functional deficiency.
HomocysteineEveryoneInterpret with B12, folate and MMA; vascular and nutritional confounders.
CBCEveryoneAnemia and macrocytosis. Hemoglobin also matters for p-tau217 interpretation (anemia lowers its positive predictive value).
CMPEveryoneRenal function (eGFR) for p-tau217 interpretation; sodium, glucose and liver function as reversible contributors.
TSHRoutine, about yearlyRepeat sooner with known thyroid disease, abnormal prior results, dose changes, or adherence concerns.
Syphilis serology (RPR)Appropriate populationWhen history or risk factors suggest it. A 5-year lookback is reasonable; repeat sooner with new sexual history or risk.
Plasma p-tau217 (Mayo PT217)MoCA 26 or below, or objective impairment, and AD is in the differentialNot more than yearly unless monitoring AAT. Do not order for memory concerns NOS, worried-well, or family members. An existing dementia diagnosis is not an exclusion if never biomarker-tested.
Plasma Aβ42/40, p-tau181Not for routine PCP usePre-analytic handling issues; keep the PCP pathway centered on p-tau217.

Interpreting p-tau217 with comorbidity

CKD
No validated eGFR cutoff for ordering, but renal dysfunction raises p-tau217. With eGFR below 60, interpret borderline or intermediate results cautiously and consider PET or CSF confirmation. In CKD stage 4–5, p-tau217 has very limited stand-alone value.
Anemia
Can reduce the positive predictive value of an elevated result — interpret positive or borderline results more cautiously. Not a reason to avoid ordering.
Anticoagulation
Does not prevent biomarker testing. Test when AD concern is strong, and document that current anticoagulation may make the patient ineligible for infusion therapy.
Disease-modifying therapy

Anti-amyloid therapy (AAT): what IM needs to know

Obvious reasons a patient is not a candidate

  • Moderate or severe dementia (needs help with basic self-care)
  • Anticoagulation (warfarin, DOACs). Dual antiplatelet therapy unless it can be modified — single antiplatelet (aspirin or clopidogrel) is acceptable
  • Immunosuppressants or DMARDs (hydroxychloroquine and apremilast exempt; others need a 3-month washout)
  • MRI: more than 4 microbleeds, more than one area of superficial siderosis, any prior macrohemorrhage, large stroke, CAA-related inflammation; stroke, TIA or bleed in the past year
  • Shunts or prior craniotomy; inability to have MRI
  • Severe cardiac, hepatic or renal disease, active cancer, bleeding disorder. ESRD or dialysis generally excluded; CKD stage 4 individually reviewed; mild–moderate CKD alone is not an exclusion
When unsure, refer. Final eligibility is always decided by the neurocognitive physician.

Minimum workup for a direct AAT referral

  • Serum biomarker: p-tau217 (or p-tau181)
  • MRI brain within 12 months including SWI (or it will be repeat-ordered)
  • Cognitive screen on record: MoCA or MMSE

An incomplete workup routes to other neurology resources first, which adds time.

Anticoagulated with suspected AD

  • Still test when AD suspicion is strong; tell the patient they may not currently qualify for infusion.
  • Cardiology or the prescribing clinician decides whether anticoagulation can change. In selected atrial fibrillation cases, left atrial appendage occlusion (Watchman or Amulet) could permit future treatment. Permanent indications may preclude AAT.

The agents

Lecanemab (Leqembi)Donanemab (Kisunla)
TargetSoluble Aβ protofibrilsDeposited plaque (N-terminal pyroglutamate Aβ)
DosingIV every 2 weeks, ongoingIV every 4 weeks; may stop after plaque clearance
Efficacy (trials)27% slowing on CDR-SB at 18 monthsAbout 35% slowing on iADRS in low/medium tau; 22–29% overall
ARIA-E (trial)12.6%24.0% standard; 15.6% modified titration
Surveillance MRIBaseline, then before infusions 3, 5, 7, 14Baseline, then before infusions 2, 3, 4, 7

These drugs slow decline; they do not stop or reverse disease. Best responses occur with milder symptoms and lower tau burden.

Your role while a patient is on AAT

  • Do not start anticoagulation or immunosuppression without contacting the AAT team — both affect eligibility and safety.
  • New headache, confusion, visual change, focal deficits or seizure: treat as possible ARIA — obtain MRI and contact the team; ED via the ARIA emergency protocol if acute.
  • Infections (including COVID), surgery, falls or head injury raise ARIA risk — notify the team; infusions may be paused.
  • Delayed fever, chills or malaise after repeated infusions can be a serum sickness-like reaction — report to the team.
  • Keep vascular risk tightly controlled; continue cholinesterase inhibitors or memantine at a stable dose.
  • Prior authorization takes at least two weeks; Medicare patients need CMS registry enrollment (handled by the program).
Longitudinal

Ongoing care, sleep, driving & safety

Longitudinal management in primary care

  • Normal testing with a complaint: rescreen periodically (MoCA every 6–12 months; CANTAB when available).
  • Mild cognitive decline: APP follow-up about every 6 months, with RN support for education, social work and palliative coordination.
  • Biomarker-negative, too advanced, or ineligible for AAT: these patients should not be stranded — use general neurology, palliative medicine and the 85+ pathway as appropriate.
  • Vascular and lifestyle risk: blood pressure, glucose, lipids, hearing, physical activity, alcohol, mood.
  • Advance care planning, caregiver assessment and safety review at each visit.
  • Palliative care partnership: neurology co-manages behavior; palliative care handles throughput, longitudinal monitoring and hospice. A transition, not abandonment — with a PRN path back to neurology.

Sleep, step by step

  1. Avoid benzodiazepines, zolpidem-type drugs, diphenhydramine and “PM” products.
  2. Start melatonin; next trazodone or a DORA such as suvorexant (prior authorization; send to Ochsner Main Campus pharmacy).
  3. Refer to Sleep Medicine — untreated sleep apnea is common and treatable.
  4. If a DORA fails, look for the cause (apnea, pain, nocturia, mood, medications) rather than adding sedation.

Driving

  1. Ask and document (getting lost, near-misses, tickets, dents). Encourage voluntary cessation and plan transportation.
  2. If they want to keep driving, recommend an OT driving evaluation (may be self-pay) and let the evaluation decide.
  3. If both are refused, report to the Office of Motor Vehicles with the Driver Behavior Report (DPSMV 3005). Louisiana does not require physician reporting; good-faith reports are protected.

Emergencies & protective services

SituationAction
Sudden confusion, new weakness or speech change, seizureEmergency Department the same day.
Acute agitation or aggression the family cannot manageEmergency Department; 911 for immediate danger.
Firearm in the homeAsk every visit. Remove, or lock away unloaded with ammunition separate and the key kept from the patient. Immediate danger: 911.
Suspected abuse, neglect, self-neglect, exploitationAge 60+: Elderly Protective Services 1-833-577-6532 (weekdays 8:00–4:30), after hours 1-844-945-2377.
Age 18–59: Adult Protective Services 1-800-898-4910 (24/7). Louisiana requires reporting.

Before-you-refer checklist

0 of 12

Nothing is saved or sent — it’s a scratch list for the visit you’re in.

Who to contact

  • AAT candidates, cognitive clinic triage, expedites
    Neurocognitive triage pool (secure chat)
  • CAA Clinic referrals
    CAA Clinic 504-842-6179
  • Vascular cognitive impairment, CAA, bleeding questions
    CAA Clinic vascular neurology team
  • MRI, biomarker, or unclear cognitive questions
    Neurocognitive Program physicians, through the triage pool
  • Patients checking referral status
    Neurocognitive Program 504-842-3980
  • Self-triage education for patients

Clinical guidance for Ochsner internal medicine and primary care clinicians, from the Ochsner Neurocognitive Program (November 2026). It supports — and does not replace — clinical judgment; final anti-amyloid eligibility is decided by the neurocognitive physician. See also the Ochsner Neurocognitive Program and Ochsner CAA Program.